Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension

The TOMORROW trial of nintedanib comprised a randomised, placebo-controlled, 52-week period followed by a further blinded treatment period and an open-label extension. We assessed outcomes across these periods in patients randomised to nintedanib 150 mg twice daily or placebo at the start of TOMORRO...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Thorax
Main Authors: Richeldi, Luca, Kreuter, Michael, Selman, Moisés, Crestani, Bruno, Kirsten, Anne-Marie, Wuyts, Wim A, Xu, Zuojun, Bernois, Katell, Stowasser, Susanne, Quaresma, Manuel, Costabel, Ulrich
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2018
Assuntos:
Research Letter
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5969333/
https://ncbi.nlm.nih.gov/pubmed/28993537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/thoraxjnl-2016-209701
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados